Abridge priced for Epic distribution
Abridge
The 53x multiple is really a price on distribution, not just software. In hospital AI scribes, the hardest part is not turning speech into a note, it is getting deep enough into Epic that the note, diagnoses, orders, codes, and billing data flow back into the clinician’s actual workflow. Abridge’s lead comes from being one of only two Epic development partners, which helped it scale from about 8,000 to more than 60,000 clinicians across 100 plus health systems and reach about $100M ARR by May 2025.
-
Abridge’s edge is integration depth. In practice, that means doing more than dropping a transcript into the chart. The system can structure the note, surface codes and modifiers, and feed data into downstream workflows. That is why health systems often choose between Abridge and Nuance at the top of the market, while lighter products compete lower down.
-
The multiple stands out even inside the same category. Abridge was valued at $5.3B on about $100M ARR, versus Ambience at about $1B on $30M ARR, and far above older scribe businesses like Augmedix, which sold at about 3x revenue. Investors are paying up for the company that appears closest to becoming the default add on inside Epic hospitals.
-
That position also shapes the business model. The Epic relationship appears to involve equity and revenue sharing, which narrows Abridge’s room to compete directly with Epic in core EHR modules, but it gives Abridge a faster path into large health systems where IT, compliance, and executive buyers matter more than individual doctor preference.
The next leg is turning ambient documentation into a broader clinical workflow layer. Abridge is already pushing from note creation into coding, prior authorization, and inpatient nursing workflows, which can raise revenue per deployment and make the Epic partnership even more valuable as hospitals look for one embedded copilot across more care settings.